Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Test Vans to Hit Rural Roads (China)

This article was originally published in PharmAsia News

Executive Summary

The final batch of on-the-spot drug test vans will hit the roads of rural China in September as part of the nation's effort to fight counterfeit drugs. The State Food and Drug Administration will provide a total of 370 vans equipped with testing facilities to local food and drug watchdogs, says Yan Jiangying, a spokeswoman for the administration. "This kind of mobile inspection of drug quality will benefit consumers, especially the vast rural population," Yan says. "The move is part of a nationwide campaign to crack down on the production and sale of fake drugs, and bring order to the drug market," she adds. Cheng Chuanghong, a director with the National Institute for the Control of Pharmaceutical and Biological Products, which devised the program, says 338 of the vans were already in operation in 27 provinces. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel